Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417530 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
A Phase 2 study, sponsored by Aura Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT04417530 is a Phase 2 study that has completed, run by Aura Biosciences. The registered enrollment target is 22 participants.
The verdict
NCT04417530, a Phase 2 study, has completed, sponsored by Aura Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
Interventions
- DRUG AU-011
- DEVICE Suprachoroidal Microinjector
- DEVICE PDT Laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2024-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417530
The ClinicalTrials.gov registry entry for NCT04417530 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aura Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AU-011 is the first listed.
NCT04417530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04417530 about?
NCT04417530 is a clinical study titled "Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma". The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
What is the current status of trial NCT04417530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2020-08-05. Estimated completion is 2024-04-22.
What interventions are being tested in trial NCT04417530?
The interventions under investigation include: AU-011 (DRUG), Suprachoroidal Microinjector (DEVICE), PDT Laser (DEVICE).
Who is sponsoring clinical trial NCT04417530?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.